The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
- PMID: 26973128
- DOI: 10.2217/imt-2015-0002
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
Abstract
Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer.
Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines.
Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06).
Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.
Keywords: PD1; anti-PDL1; clinical trials; lung cancer; meta-analysis; nivolumab; non-small-lung cancer; pembrolizumab.
Similar articles
-
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.Immunotherapy. 2016 Sep;8(9):1011-9. doi: 10.2217/imt-2016-0032. Immunotherapy. 2016. PMID: 27485075
-
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.Immunotherapy. 2017 May;9(6):499-506. doi: 10.2217/imt-2016-0150. Immunotherapy. 2017. PMID: 28472902 Review.
-
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015. PLoS One. 2015. PMID: 26086854 Free PMC article.
-
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.Clin Lung Cancer. 2016 Jul;17(4):263-270.e2. doi: 10.1016/j.cllc.2015.11.006. Epub 2015 Dec 1. Clin Lung Cancer. 2016. PMID: 26707383
-
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.Curr Opin Oncol. 2016 Mar;28(2):122-9. doi: 10.1097/CCO.0000000000000263. Curr Opin Oncol. 2016. PMID: 26756384 Review.
Cited by
-
Nanomedicines Targeting Tumor Cells or Tumor-Associated Macrophages for Combinatorial Cancer Photodynamic Therapy and Immunotherapy: Strategies and Influencing Factors.Int J Nanomedicine. 2024 Oct 4;19:10129-10144. doi: 10.2147/IJN.S466315. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39381025 Free PMC article. Review.
-
Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab.In Vivo. 2024 Sep-Oct;38(5):2434-2440. doi: 10.21873/invivo.13712. In Vivo. 2024. PMID: 39187353 Free PMC article.
-
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.Cancer Med. 2024 Apr;13(8):e7154. doi: 10.1002/cam4.7154. Cancer Med. 2024. PMID: 38629258 Free PMC article.
-
Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma.J Korean Soc Radiol. 2024 Mar;85(2):394-408. doi: 10.3348/jksr.2023.0011. Epub 2024 Mar 26. J Korean Soc Radiol. 2024. PMID: 38617847 Free PMC article.
-
S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function.J Exp Clin Cancer Res. 2024 Mar 8;43(1):72. doi: 10.1186/s13046-024-02985-1. J Exp Clin Cancer Res. 2024. PMID: 38454445 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
